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A large fraction of mammalian genes is regulated posttranscriptionally by microRNAs. In the developing
nervous system, a small subset of these short RNA molecules is important to orchestrate the rapid switch
from OPCs to myelin-forming oligodendrocytes. But putting the miRNA brake on oligodendrocyte gene
expression is required throughout life.Oligodendrocytes are the last cell type
to differentiate in the developing brain.
In rodents, most oligodendrocytes are
generated in the first 2–3 postnatal
weeks. One function of this highly special-
ized subtype of glia, the wrapping of
axons with a multilayered myelin sheath,
is well known. The unique membrane
architecture of myelin reduces axonal
energy expenditure and provides the
physical basis for rapid impulse propaga-
tion (Lazzarini et al., 2004). There is also
growing evidence that oligodendrocytes
maintain the functional integrity of myelin-
ated axons, i.e., motor-driven transport
processes and the long-term survival of
axons, a support function that is shared
by myelin-forming Schwann cells in the
periphery. With this crucial role of glia in
neuronal function, there is an obvious
interest in better understanding the
molecular regulation of oligodendrocyte
differentiation in a number of human
myelin diseases, in which myelin either
fails to form or is secondarily lost, such
as in multiple sclerosis.
Myelination in the rodent brain and
spinal cord involves two phases of unusu-
ally high developmental dynamics: first,
the number of oligodendrocyte precursor
cells (OPCs) expands rapidly, beginning
before birth in the ventral and dorsal
embryonic spinal cord, followed by the
ganglionic eminence and the cortex of
the developing forebrain (Richardson
et al., 2006). These proliferating OPCs
migrate and populate all future white
matter tracts and are initially produced in
excess. This necessitates that oligoden-
drocytes are matched to the available
number of myelination-competent axons,
which is achieved by a combination ofrate-limiting growth and survival factors
and the electrical activity of axons on
one hand and programmed glial cell death
on the other (Barres and Raff, 1994).
Among the many factors that stimulate
the growth of OPC in culture, PDGF has
been shown most convincingly to be
a crucial driving force of proliferation
also in vivo (Calver et al., 1998). Later
and prior to myelination, a careful orches-
tration of cell cycle withdrawal and differ-
entiation is essential. Recent investiga-
tions have revealed that this involves the
coordinated repression of several tran-
scriptional inhibitors, such as Hes5, Id4,
and Tcf4 (He et al., 2007). Immediately
after cell cycle exit, myelin lipid and
protein synthesis increases dramatically
for the deposition of large amounts of
myelin membrane, a process completed
within a few days (Pfeiffer et al., 1993).
This enormous cell growth requires
unusual synthesis rates of myelin struc-
tural proteins, many of which are encoded
by cell-specificmRNAs that are present at
high copy numbers.
The switch from proliferating OPCs
that are migratory to postmitotic oligo-
dendrocytes that synthesize myelin
occurs rapidly and exactly at the time
when axon and oligodendrocyte numbers
appear to match. How is it possible to
put a sudden ‘‘brake’’ onto the pool of
progenitor cells that still express multiple
transcriptional inhibitors and live in the
continued presence of growth factors,
such as PDGF? In this issue of Neuron,
two papers from Ben Barres’ and Richard
Lu’s lab provide evidence that this switch
is aided by the expression of a set of
microRNAs (miRNAs) that are induced in
maturating OPCs (Dugas et al., 2010;Neuron 6Zhao et al., 2010). Their work suggests
a model in which posttranscriptional
attenuation of exactly those genes that
normally maintain the proliferating OPC
phenotype becomes a ‘‘brake’’ in the
system that promotes the rapid transition
of OPCs to mature oligodendrocytes.
The discovery that miRNAs provide a
new layer of gene expression control in
apparently all multicellular organisms is
one of the major breakthroughs of the
last decade (Bartel, 2004; Filipowicz
et al., 2008). It is thought that human cells
harbor about one thousand different
miRNAs, a superfamily of single-stranded
RNA molecules 20–24 nucleotides in
length. These are derived from larger
hairpin-folded precursors that are often
noncoding transcripts (‘‘pri-miRNAs’’).
Processing of pri-miRNAs to mature
miRNAs involves at least two steps.
In the nucleus, the endonuclease Drosha
generates a pre-miRNA that is exported.
In the cytosol, the RNase Dicer contin-
ues the processing to a mature single-
stranded miRNA, which incorporates
into a functional ribonucleoprotein, the
‘‘miRNA induced silencing complex’’
(miRISC).
In the 30 untranslated region (UTR) of
mRNAs, often more than one binding
site for known miRNAs can be predicted
using database mining tools and assum-
ing perfect base pairing of nucleotides
2–8 (the ‘‘seed’’). Binding of the miRISC
to the 30 UTR inhibits translational initia-
tion and can also destabilize mRNAs,
resulting in rapid degradation (which
mechanism prevails is not well under-
stood). Either way, it is estimated that
30% or more of our genes are posttran-
scriptionally regulated by miRNAs.5, March 11, 2010 ª2010 Elsevier Inc. 577
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miRNA expression is highest in the brain,
and the miRNA profile of oligodendrocyte
lineage cells has recently been estab-
lished (Lau et al., 2008). To address
functional importance, Dugas et al. and
Zhao et al. started out by generating
conditional mouse mutants, in which
the critical Dicer nuclease gene was
cell-specifically inactivated (using mice
expressing Cre recombinase under con-
trol of the Olig1, Olig2, or Cnp1 promoter
at earliest stages of oligodendrocyte
development).
In general, the consequences of Dicer
ablation are similar in the two studies.
Lack of visible myelin sheaths in brain
and spinal cord is associated with ataxia,
tremors, and premature death, reminis-
cent of other myelin mutants, with dif-
ferences in detail that depend on the
Cre driver line. Those that also target
Schwann cells (i.e., Cnp1-Cre) die post-
natally with a severe developmental
defect of the PNS. In all mutants, CNS
dysmyelination is caused by the virtual
lack of mature oligodendrocytes, as as-
sessed by late marker gene expression,
and a concomitant increase of prolifer-
ating OPCs that continue to express
PDGF receptors. The differentiation arrest
of OPCs is cell autonomous (i.e., not
caused by axonal signaling problems),
as evidenced by similar defects of purified
OPCs, maintained under conditions that
should promote their differentiation. Inter-
estingly, in older mice, CNS myelination
appears not to be blocked, but only
severely delayed. This, however, is likely
due to the expansion of OPCs that have
simply escaped Cre-mediated recombi-
nation. Thus, the current analysis has
been largely restricted to early stages of
development.
Dicer ablation may be considered a
crude and unspecific insult to cells, pro-
mpting the question of which miRNAs
are so important for the differentiation
of OPC? Out of several hundreds, few
candidate genes were narrowed down
by focusing onto miRNAs that showed
a regulated expression in oligodendro-
cyte lineage cells (Barres lab) or were
abundant in developing white matter
tracts (Lu lab) and which could be con-
firmed by northern blotting and in situ
hybridization experiments. These differ-
ences at the outset might explain why an578 Neuron 65, March 11, 2010 ª2010 Elsevoverlapping but not identical set of top
candidates emerged in these studies.
Importantly, both groups confirmed the
presence of miRNAs that were identified
in independent studies, notably miR-219
(Lau et al., 2008; Shin et al., 2009), but
also went an important step further by
demonstrating functional significance for
differentiation.
The role of specific miRNA can be
tested by either adding ‘‘mimetics’’ to
cultured cells (i.e., chemically modifed
oligonucleotides that efficiently mimic
a specific miRNA species) or correspond-
ing ‘‘inhibitors’’ (i.e., blocking anti-sense
oligonucleotides that inhibit endogenous
miRNAs). In these in vitro experiments,
OPCs were either induced with PDGF
to continue proliferating or were forced
to exit the cell cycle and to differentiate
(–PDGF/serum removal; also thyroxin
was used to stimulate differentiation).
Under most conditions, although not in
all, miR-219 emerged as a dominant
player that enhanced the expression of
all myelin protein genes analyzed. Inter-
estingly, when Dicer mutant OPCs were
tested by complementation, miR-219
alone appeared to ‘‘rescue’’ a significant
fraction of cells from a developmental
arrest, at least when judged by the
expression of MBP, a late myelin protein
marker.
What are the critical target genes of
developmentally expressed miRNAs in
oligodendrocytes, suchasmiR-219 (which
may also have a neuronal function;
see Kocerha et al., 2009)? By scanning
the 30 UTR of mRNAs that were previously
found in oligodendrocyte lineage cells
for the presence of conserved miRNA
binding sites, several promising candidate
genes were picked. Importantly, this
included among others the gene for
PDGFR alpha, the very receptor tyrosine
kinase whose activation keeps OPCs
proliferating and undifferentiated in vitro
and in vivo. Indeed, miR-219 very effi-
ciently attenuates the expression of
PDGFR alpha at the protein level, and
this effect is clearly dependent on the
identified miR-219 binding site in the
30 UTR. Similarly, the transcriptional inhib-
itors of differentiation Hes5 and Sox6 are
downregulated by miR-219. Thus, while
the true regulatory network of miRNA-
controlled genes in oligodendrocytes
is undoubtedly much more complex,ier Inc.already a simple working model (Figure 1)
can be sketched with these observations.
Upon serum or PDGF withdrawal from
cultured OPCs (the in vivo correlate is
not so clear), the expression of miR-219
is induced, which then ‘‘inhibits the inhib-
itors,’’ e.g., it rapidly downregulates the
responsiveness of OPCs to PDGF stimu-
lation. Repressing PDGFR alpha and
Hes5 expression further enhances oligo-
dendrocyte differentiation and creates
a positive feedback loop (Figure 1). This
model may also explain the irreversible
nature of differentiation, an issue perhaps
relevant to the role of miRNAs in cancer.
It also fits the overall concept that micro-
RNAs have evolved to control the timing
of cell division and differentiation in organ
development (Pasquinelli and Ruvkun,
2002).
The late differentiation of oligodendro-
cytes in the mammalian brain has
the remarkable consequence that even
severe developmental defects cause
dys- and demyelinating disease (in chil-
dren with leukodystrophies) rather than
embryonic lethality. One common feature
of some leukodystrophies is the apparent
inability of myelinating glia to handle ele-
vated copy numbers of genes for abun-
dant membrane proteins. For example,
duplications of PLP1 are the most fre-
quent cause of demyelination and axon
loss in Pelizaeus-Merzbacher disease. It
is plausible that cells, already geared for
high-level membrane synthesis, cannot
tolerate protein overexpression due to
the associated ER stress. Also in the adult
brain, the steady-state level of many
myelin protein mRNAs appears higher
than predicted for myelin membrane
turnover. This raises the possibility that
mature oligodendrocytes also require
posttranscriptional mechanisms to con-
trol the expression of myelin-associated
genes.
Support for this idea comes from
a study of Louis Ptacek’s and Ying-Hui
Fu’s lab, reported in the first of the three
recently published papers on Dicer
and miRNA function in oligodendrocytes
(Shin et al., 2009). In this study, Dicer
expression was disrupted in mature
oligodendrocytes of adult mice, using
tamoxifen-inducible Cre recombination
under control of the Plp1 promoter.
Thus, bypassing the critical early stages
of development, these mutant mice
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Figure 1. MicroRNA-Mediated Loss of Progenitor Properties Causing Rapid Oligodendrocyte Differentiation
In this model, the proliferation of OPC (left) is stimulated by gowth factors (+PDGF), and the differentiation into oligodendrocytes (right) is prevented by transcrip-
tional inhibitors (e.g., Hes5 and Sox6). Following serum removal (–PDGF), the induction miR-219 and other miRNAs, processed by Dicer, is a "brake" on the
expression of transcriptional inhibitors and PDGF receptor (middle, other target genes not shown). This lack of PDGF responsiveness and transcriptional
inhibition constitutes a positive feed back loop that promotes amore rapid differentiation. In mature oligodendrocytes, the samemiRNA regulates genes for other
proteins, such as fatty acid elongase ELAVL7.
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phenotype later in life, which included
demyelination, inflammatory changes,
and axon loss. Using very similar tech-
niques as used in this year’s papers, the
authors identified miR-219 as the most
interesting candidate miRNA, and deter-
mined its binding site in a regulated target
gene. This gene, however, encodes an
enzyme (ELAVL7) for the synthesis of
very long chain fatty acids, which marks
the ‘‘far end’’ of oligodendrocyte differen-
tiation. Again, also the inducible Dicer
mutant phenotype is complex, and the
cause of demyelination is not under-
stood yet, but miRNAs (such as miR-
219) appear to be critical for regulating
gene expression also in mature oligoden-
drocytes.
Collectively, these papers have identi-
fied the expression of miRNAs as a post-
transcriptional ‘‘brake’’ of gene expres-
sion that remains essential throughout
the lifespan of oligodendrocytes.
Given the sensitivity of all myelinating
glia to the overexpression of myelinmembrane proteins and the intriguing
finding that a clinically relevant myelin
protein, PMP22, is regulated by miR-29A
(Verrier et al., 2009), one wonders how
soon miRNAs themselves will be associ-
ated with a human myelin disease.REFERENCES
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